CATX: Perspective Therapeutics Analyst Consensus Forecast

Corporate company logo of Perspective Therapeutics (CATX)

This price trend chart for Perspective Therapeutics (CATX) illustrates the dynamics of a company developing targeted isotope delivery systems for tumors, where the indicator stands at 9.49. The business model relies on patent protection and profit growth as clinics expand. Human capital is being strengthened by attracting nuclear medicine experts through stock options. Development efficiency is increased by outsourcing substance synthesis and testing to external contractors.

CATX - Perspective Therapeutics Inc Consensus Target over the range 06/21/2023 - 11/11/2026

Metric breakdowns and analytics for Perspective Therapeutics (CATX)

- market price and analyst price targets:
Stock Quotes perspectivetherapeutics.com|CATX - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Perspective Therapeutics Inc|CATX - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Price of a Share Perspective Therapeutics|CATX - Company Net Assets|Capitalization to Book Value Ratio perspectivetherapeutics.com|CATX - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Capital Perspective Therapeutics|CATX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio perspectivetherapeutics.com|CATX - Company Aggregate Debts|Debt to Book Value Perspective Therapeutics Inc|CATX - Company Long-Term Debt|Short-Term Debt Perspective Therapeutics|Quick Liquidity perspectivetherapeutics.com
- earnings and market ratios statistics:
CATX - Company Net Income|Expected Net Profit Perspective Therapeutics|CATX - P/E Multiple|Forward Price to Earnings Multiple perspectivetherapeutics.com|CATX - Price/Earnings to Growth Multiple|Company Value to EBITDA Perspective Therapeutics Inc|CATX - Operating profit before deduction of amortization|Earnings per share for the trailing year Perspective Therapeutics|CATX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months perspectivetherapeutics.com|CATX - Earnings per share growth in current year|Net earnings per share growth forecast for next year Perspective Therapeutics
General company analysis:CATX (Perspective Tx)
Mass-produced product of Perspective Tx

Experts determine the investment potential of Perspective Therapeutics (CATX) through a weighted average target price, which measures the fundamental gap between the current quote and the expected market equilibrium. By analyzing the consensus target price, investors assess the future capitalization of R&D projects in the absence of operating profit and amidst constant capital burn, which is characteristic of high-risk biotech assets.

Competitors of Perspective Therapeutics

Consensus Target geron.com GERN|Analyst Consensus Forecast NBTX (Nanobiotix)|Analyst Consensus Forecast Bicycle Therapeutics PLC BCYC|CTMX: Consensus Target|Genelux Corporation - Analyst Forecast Prices|MOLN (Molecular Partners) - Consensus Target|Broker Consensus Forecast ONCY|Price Target Chart Lisata Therapeutics Inc.|Average Forecast Price Moleculin MBRX|Price Target Chart Galera Therapeutics (GRTX)|Molecular Templates Corporation - Broker Consensus Forecast